Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Mereo BioPharma (MREO) Income from Continuing Operations (2023 - 2025)

Mereo BioPharma (MREO) has disclosed Income from Continuing Operations for 3 consecutive years, with 7351000.0 as the latest value for Q4 2025.

  • Quarterly Income from Continuing Operations fell 4.33% to 7351000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 41878000.0 through Dec 2025, up 3.18% year-over-year, with the annual reading at 41878000.0 for FY2025, 3.18% up from the prior year.
  • Income from Continuing Operations for Q4 2025 was 7351000.0 at Mereo BioPharma, down from 7024000.0 in the prior quarter.
  • The five-year high for Income from Continuing Operations was 1751000.0 in Q2 2023, with the low at 15001000.0 in Q3 2024.
  • Average Income from Continuing Operations over 3 years is 9638500.0, with a median of 9562000.0 recorded in 2023.
  • The sharpest move saw Income from Continuing Operations crashed 599.89% in 2024, then skyrocketed 53.18% in 2025.
  • Over 3 years, Income from Continuing Operations stood at 10173000.0 in 2023, then skyrocketed by 30.74% to 7046000.0 in 2024, then dropped by 4.33% to 7351000.0 in 2025.
  • According to Business Quant data, Income from Continuing Operations over the past three periods came in at 7351000.0, 7024000.0, and 14616000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.